Corporate GovernanceJun 4, 2026, 05:22 PM
Pacific Biosciences Stockholders Approve 16M Share Increase for Equity Plan
AI Summary
Pacific Biosciences of California, Inc. announced that its stockholders approved an amendment to the 2020 Equity Incentive Plan, reserving an additional 16,000,000 shares of common stock for issuance. The Annual Meeting also saw the election of four Class III directors, the ratification of Ernst & Young LLP as the independent auditor for 2026, and the advisory approval of named executive officer compensation. Approximately 65% of the company's outstanding shares were represented at the meeting.
Key Highlights
- Stockholders approved an amendment to the 2020 Equity Incentive Plan, reserving an additional 16,000,000 shares.
- Four Class III directors were elected to serve until the 2027 annual meeting of stockholders.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Named executive officer compensation was approved on a non-binding advisory basis.
- Approximately 65% of outstanding shares (203,009,375 shares) were represented at the Annual Meeting.
- The 2020 Plan amendment received 114,865,820 "For" votes from stockholders.
- The advisory vote on executive compensation received 114,050,930 "For" votes.
Price Impact
More from PACB